MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2644
Registration Number
NCT02248155

Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: ALNA®
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3629
Registration Number
NCT02244268

Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: alpha-adrenergic blocker
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4561
Registration Number
NCT02244307

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Tipranavir
Drug: Ritonavir
Drug: Methadone
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT02245451

FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)

Phase 2
Completed
Conditions
Prostate Hyperplasia
Interventions
Drug: FLOMAX® capsules
Drug: Placebo capsules
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
176
Registration Number
NCT02244294

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Tamsulosin
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
982
Registration Number
NCT02245529

Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: ALNA®
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4575
Registration Number
NCT02244333

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

Phase 4
Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Tamsulosin hydrochloride
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
493
Registration Number
NCT02244242

Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

Completed
Conditions
Hypertension
Interventions
Drug: Telmisartan
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13066
Registration Number
NCT02245464

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Tamsulosin
First Posted Date
2014-09-19
Last Posted Date
2014-09-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
7391
Registration Number
NCT02245503
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy